Halozyme Therapeutics (LTS:0J2O) Common Stock : $0.1 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Halozyme Therapeutics Common Stock?

Halozyme Therapeutics's quarterly common stock declined from Sep. 2023 ($0.1 Mil) to Dec. 2023 ($0.1 Mil) but then stayed the same from Dec. 2023 ($0.1 Mil) to Mar. 2024 ($0.1 Mil).

Halozyme Therapeutics's annual common stock declined from Dec. 2021 ($0.1 Mil) to Dec. 2022 ($0.1 Mil) and declined from Dec. 2022 ($0.1 Mil) to Dec. 2023 ($0.1 Mil).

Halozyme Therapeutics Common Stock Historical Data

The historical data trend for Halozyme Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Common Stock Chart

Halozyme Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.14

0.13

Halozyme Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.13	0.13	0.13	0.13	0.13

Halozyme Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Halozyme Therapeutics (LTS:0J2O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (LTS:0J2O) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

HALO:USA RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics (LTS:0J2O) Headlines

No Headlines